Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population
- 78 Downloads
Purpose of Review
This review aims to synthesise the current literature on the management of early-stage and metastatic esophageal cancers, focusing on the older population. In particular, we aim to dissect out the elderly-specific data from the relevant trials and to discuss the issues unique to this population.
While surgery is the curative modality in esophageal malignancies, the CROSS, MAGIC and FLOT trials demonstrate a clear advantage to neoadjuvant therapy (chemotherapy and chemoradiotherapy). These trials, however, included few elderly patients. There is a similar lack of elderly-specific data in the metastatic setting.
Esophageal malignancies remain highly lethal with increasing incidence with age. Despite the relative lack of elderly-specific data, the fit older population appear to similarly benefit from multimodal therapy in early-stage and palliative therapy in metastatic disease.
KeywordsCancer Oesophagus Oesophago-gastric junction Elderly Chemotherapy
Compliance with Ethical Standards
Conflict of Interest
Dara Bracken-Clarke, Abdul Rehman Farooq, and Anne M. Horgan declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.SEER Cancer Statistics Review, 1975-2015 [Internet]. Surveillance Research Program of the NCI. 2018. Available from: https://seer.cancer.gov/csr/1975_2015/.
- 2.• van Putten M, de Vos-Geelen J, Nieuwenhuijzen GAP, Siersema PD, Lemmens V, Rosman C, et al. Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer. 2018;94:138–47 This article reports the trends in diagnosis, treatment, histology and survival for oesophageal cancer in the Netherlands Cancer Registry in the period 1989–2014. It reports incidence, subtype, survival, age and treatment modality—thus yielding extensive demographic and therapeutic data across time. PubMedGoogle Scholar
- 3.•• van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84 This article reports the Dutch CROSS trial, assessing the efficacy of neoadjuvant chemoradiotherapy (carboplatin/paclitaxel, 41.4Gy) followed by surgery vs surgery alone for locally advanced oesophageal cancer. Although fewer older patients were included, it represents a worldwide standard-of-care for trimodality therapy in oesophageal cancer. Thus, it remains highly relevant in any treatment plan for locally advanced disease. PubMedGoogle Scholar
- 4.• Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis. 2017;9(Suppl 8):S792–S8 This review discusses the various regimens (both chemotherapy and radiotherapy) used for radical treatment of oesophageal cancer. There is less focus on age however side effect data and long-term remission rate with chemoradiotherapy +/- surgery—which may be a very important factor in the older population. PubMedPubMedCentralGoogle Scholar
- 7.•• Guttmann DM, Mitra N, Metz JM, Plastaras J, Feng W, Swisher-McClure S. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer. J Geriatr Oncol. 2018;9(1):40–6 This article reports a large observational cohort study of neoadjuvant chemoradiotherapy specifically in an older population. It confirms the efficacy and tolerability of trimodality therapy in the elderly, confirming previous extrapolations from the CROSS study. Thus, it offers clear evidence for this approach in the elderly and is relevant to treatment decisions in this population. PubMedGoogle Scholar
- 39.Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol. 2016;34(23):2736–42.PubMedPubMedCentralGoogle Scholar
- 40.Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–53.PubMedGoogle Scholar
- 41.Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.PubMedGoogle Scholar
- 42.Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996–2004.PubMedGoogle Scholar
- 50.Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol. 2010;36(3):601–6.PubMedPubMedCentralGoogle Scholar
- 52.Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–7.PubMedGoogle Scholar
- 53.Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer. 2013;49(4):835–42.PubMedGoogle Scholar
- 59.Kassam Z, Wong RK, Ringash J, Ung Y, Kamra J, DeBoer G, et al. A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol). 2008;20(1):53–60.Google Scholar
- 65.Mocanu A. Endoscopic palliation of advanced esophageal cancer. J Med Life. 2015;8:193–201.Google Scholar
- 68.Ye X-J, Ji Y-B, Ma B-W, Huang D-D, Chen W-Z, Pan Z-Y, et al. Comparison of three common nutritional screening tools with the new European Society for Clinical Nutrition and Metabolism (ESPEN) criteria for malnutrition among patients with geriatric gastrointestinal cancer: a prospective study in China. BMJ Open. 2018;8(4):e019750.PubMedPubMedCentralGoogle Scholar
- 69.• Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102:966 This article reports the incidence of malnutrition in an undifferentiated French oncology population. It is relevant both to the underlying incidence of malnutrition and to its impact on survival. PubMedPubMedCentralGoogle Scholar
- 70.• Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16:21 This article reports overall sarcopaenia rates worldwide in the older population—which continue to rise with advancing age. This is of particular relevance to oesophageal cancer given the significantly increased complications (especially surgical complications) associated with sarcopaenia. PubMedPubMedCentralGoogle Scholar
- 82.Harari D, Hopper A, Dhesi J, Babic-Illman G, Lockwood L, Martin F. Proactive care of older people undergoing surgery ('POPS'): designing, embedding, evaluating and funding a comprehensive geriatric assessment service for older elective surgical patients. Age Ageing. 2007;36(2):190–6.PubMedGoogle Scholar
- 88.Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.Google Scholar